GlassScriptPhysician profile
Crystal D Davison
NPI 1467728089
$15,684.05
in general payments reported to CMS, 2019-2025
46 companies · $4,591 in 2025
The $4,591 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $401 · 2022: $3,465 · 2023: $3,519 · 2024: $3,708 · 2025: $4,591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $355 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,313.64 |
| Education | $354.61 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,172.73 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Jazz Pharmaceuticals INC. | $1,820.89 | 2021-2025 | |
| Inspire Medical Systems, INC. | $1,646.07 | 2022-2024 | Inspire |
| Harmony Biosciences LLC | $1,490.31 | 2021-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $1,479.29 | 2021-2025 | Dupixent |
| Genzyme Corporation | $1,159.22 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $835.51 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $819.53 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Axsome Therapeutics, INC. | $766.09 | 2023-2025 | Sunosi |
| Amgen INC. | $296.35 | 2022-2025 | Tezspire |
| United Therapeutics Corporation | $285.08 | 2023-2025 | |
| Grifols USA, LLC | $273.88 | 2022-2025 | Prolastin-C Liquid |
| Avadel Cns Pharmaceuticals, LLC | $247.58 | 2024-2025 | Lumryz |
| Insmed, INC. | $202.75 | 2024-2025 | Arikayce, Brinsupri |
| Genentech USA, INC. | $197.73 | 2021-2025 | Xolair |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $193.82 | 2023-2025 | Remede System |
| Takeda Pharmaceuticals U.S.A., INC. | $188.04 | 2024-2025 | Glassia |
| Ascendis Pharma Endocrinology INC | $162.86 | 2025 | Yorvipath |
| Viatris Specialty LLC | $155.70 | 2025 | Yupelri |
| Lilly USA, LLC | $147.51 | 2024-2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $105.22 | 2022-2024 | |
| Baxter Healthcare | $102.91 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 205 Acute Care |
| Mylan Specialty L.P. | $100.59 | 2022-2023 | Yupelri |
| Xeris Pharmaceuticals, INC. | $92.88 | 2024-2025 | Keveyis, Recorlev |
| Verona Pharma, INC. | $76.29 | 2025 | Ohtuvayre |
| Neurocrine Biosciences, INC. | $73.01 | 2025 | |
| Electromed, INC. | $54.73 | 2024-2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $51.03 | 2022-2024 | Opsumit, Uptravi |
| Inogen, INC. | $48.25 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $46.69 | 2022-2024 | Quviviq |
| Mallinckrodt Hospital Products INC. | $45.69 | 2023 | Acthar |
| Philips North America LLC | $44.08 | 2024-2025 | (Ak6) Vest Therapy, Encore |
| Bayer Healthcare Pharmaceuticals INC. | $42.31 | 2022-2023 | |
| Vifor Pharma, INC. | $30.68 | 2024-2025 | Veltassa |
| Radius Health, INC. | $30.09 | 2024 | Tymlos |
| Masimo Corporation | $24.23 | 2022 | |
| Sequel Med Tech, LLC | $24.04 | 2025 | Twiist |
| Beta Bionics, INC. | $22.44 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbvie INC. | $21.35 | 2024 | |
| Kaleo, INC. | $18.83 | 2023 | Auvi-Q |
| Resmed Corp | $18.17 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $14.34 | 2023 | |
| Azurity Pharmaceuticals, INC. | $14.00 | 2025 | Alvesco |
| Pulmonx Corporation | $13.95 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Covis Pharma Gmbh | $13.77 | 2022 | |
| Corcept Therapeutics | $13.54 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Davison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.